Journey Medical Corp (DERM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Journey Medical Corp (DERM) has a cash flow conversion efficiency ratio of -0.200x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($31.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Journey Medical Corp to measure how many days the company can operate on defensive assets alone.
Journey Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Journey Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Journey Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Journey Medical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CLIO Cosmetics Co.Ltd
KQ:237880
|
0.015x |
|
Cheops Technology France SA
PA:MLCHE
|
N/A |
|
Singular People S.A.
MC:SNG
|
0.140x |
|
Diamond Building Products Public Company Limited
BK:DRT
|
0.054x |
|
Yunsung F&C Co. Ltd.
KQ:372170
|
-0.111x |
|
Englewood Lab Inc
KQ:950140
|
0.044x |
|
UVAT Technology Co Ltd
TWO:3580
|
-0.038x |
|
Southern Hydropower JSC
VN:SHP
|
0.102x |
Annual Cash Flow Conversion Efficiency for Journey Medical Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Journey Medical Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see DERM company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $31.85 Million | $-12.44 Million | -0.391x | +14.12% |
| 2024-12-31 | $20.07 Million | $-9.13 Million | -0.455x | -276.62% |
| 2023-12-31 | $20.35 Million | $5.24 Million | 0.257x | +132.31% |
| 2022-12-31 | $16.98 Million | $-13.53 Million | -0.797x | -1436.30% |
| 2021-12-31 | $42.04 Million | $-2.18 Million | -0.052x | -110.40% |
| 2020-12-31 | $10.29 Million | $5.13 Million | 0.499x | -84.78% |
| 2019-12-31 | $2.75 Million | $9.02 Million | 3.277x | -86.10% |
| 2018-12-31 | $-9.04 Million | $-213.10 Million | 23.575x | +3493.55% |
| 2017-12-31 | $149.65 Million | $-103.96 Million | -0.695x | -131.88% |
| 2016-12-31 | $247.37 Million | $-74.11 Million | -0.300x | -14.71% |
| 2015-12-31 | $185.47 Million | $-48.44 Million | -0.261x | -27.73% |
| 2014-12-31 | $153.58 Million | $-31.40 Million | -0.204x | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more